{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:59:25Z","timestamp":1740135565555,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005831","name":"Foundation for Anesthesia Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"NHLBI Division of Intramural Research","doi-asserted-by":"publisher","award":["K08 HL141562"],"award-info":[{"award-number":["K08 HL141562"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypotension that is resistant to phenylephrine is a complication that occurs in anesthetized patients treated with angiotensin converting enzyme (ACE) inhibitors. We tested the hypothesis that Ang 1\u20137 and the endothelial Mas receptor contribute to vasodilation produced by propofol in the presence of captopril.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The internal diameters of human adipose resistance arterioles were measured before and after administration of phenylephrine (10<jats:sup>\u20139<\/jats:sup> to 10<jats:sup>\u20135<\/jats:sup>\u00a0M) in the presence and absence of propofol (10<jats:sup>\u20136<\/jats:sup>\u00a0M; added 10\u00a0min before the phenylephrine) or the Mas receptor antagonist A779 (10<jats:sup>\u20135<\/jats:sup>\u00a0M; added 30\u00a0min before phenylephrine) in separate experimental groups. Additional groups of arterioles were incubated for 16 to 20\u00a0h with captopril (10<jats:sup>\u20132<\/jats:sup>\u00a0M) or Ang 1\u20137 (10<jats:sup>\u20139<\/jats:sup>\u00a0M) before experimentation with phenylephrine, propofol, and A779.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Propofol blunted phenylephrine-induced vasoconstriction in normal vessels. Captopril pretreatment alone did not affect vasoconstriction, but the addition of propofol markedly attenuated the vasomotor response to phenylephrine. A779 alone did not affect vasoconstriction in normal vessels, but it restored vasoreactivity in arterioles pretreated with captopril and exposed to propofol. Ang 1\u20137 reduced the vasoconstriction in response to phenylephrine. Addition of propofol to Ang 1\u20137-pretreated vessels further depressed phenylephrine-induced vasoconstriction to an equivalent degree as the combination of captopril and propofol, but A779 partially reversed this effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Mas receptor activation by Ang 1\u20137 contributes to phenylephrine-resistant vasodilation in resistance arterioles pretreated with captopril and exposed to propofol. These data suggest an alternative mechanism by which refractory hypotension may occur in anesthetized patients treated with ACE inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-022-01786-3","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:02:52Z","timestamp":1659070972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blockade of endothelial Mas receptor restores the vasomotor response to phenylephrine in human resistance arterioles pretreated with captopril and exposed to propofol"],"prefix":"10.1186","volume":"22","author":[{"given":"Mary E.","family":"Schulz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Hockenberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boran","family":"Katunaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"1786_CR1","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.jvca.2020.07.016","volume":"35","author":"PS Pagel","year":"2021","unstructured":"Pagel PS, Tawil JN, Boettcher BT, Izquierdo DA, Lazicki TJ, Crystal GJ, Freed JK. Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. J Cardiothorac Vasc Anesth. 2021;35:1839\u201359.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1786_CR2","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet.\u00a02000;355:253\u20139.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"1786_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00000539-200101000-00006","volume":"92","author":"M Bertrand","year":"2001","unstructured":"Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg. 2001;92:26\u201330.","journal-title":"Anesth Analg"},{"key":"1786_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.jvca.2007.12.020","volume":"22","author":"S Kheterpal","year":"2008","unstructured":"Kheterpal S, Khodaparast O, Shanks A, O\u2019Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:180\u20136.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1786_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","volume":"31","author":"MC Chappell","year":"1998","unstructured":"Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1\u20137) by angiotensin-converting enzyme. Hypertension. 1998;31:362\u20137.","journal-title":"Hypertension"},{"key":"1786_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.117.10280","volume":"71","author":"F Schinzari","year":"2018","unstructured":"Schinzari F, Tesauro M, Veneziani A, Mores N, Di Daniele N, Cardillo C. Favorable Vascular Actions of Angiotensin-(1\u20137) in Human Obesity. Hypertension. 2018;71:185\u201391.","journal-title":"Hypertension"},{"key":"1786_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1161\/CIRCRESAHA.115.303881","volume":"115","author":"JK Freed","year":"2014","unstructured":"Freed JK, Beyer AM, LoGiudice JA, Hockenberry JC, Gutterman DD. Ceramide changes the mediator of flow-induced vasodilation from nitric oxide to hydrogen peroxide in the human microcirculation. Circ Res. 2014;115:525\u201332.","journal-title":"Circ Res"},{"key":"1786_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinane.2017.04.017","volume":"40","author":"H Liu","year":"2017","unstructured":"Liu H, Yu L, Yang LQ, Green MS. Vasoplegic syndrome: An update on perioperative considerations. J Clin Anesth. 2017;40:63\u201371.","journal-title":"J Clin Anesth"},{"key":"1786_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","volume":"97","author":"X Wang","year":"2016","unstructured":"Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S, Yin P, Ding Z, Kang L, Jiang Q, Zhang W, Li Y, Ge J, Zou Y. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1\u20137)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180\u201390.","journal-title":"J Mol Cell Cardiol"},{"key":"1786_CR10","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.116.08118","volume":"68","author":"S Galandrin","year":"2016","unstructured":"Galandrin S, Denis C, Boularan C, Marie J, M\u2019Kadmi C, Pilette C, Dubroca C, Nicaise Y, Seguelas MH, N\u2019Guyen D, Baneres JL, Pathak A, Senard JM, Gales C. Cardioprotective Angiotensin-(1\u20137) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor. Hypertension. 2016;68:1365\u201374.","journal-title":"Hypertension"},{"key":"1786_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/HYPERTENSIONAHA.110.152942","volume":"56","author":"SQ Savergnini","year":"2010","unstructured":"Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RA. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010;56:112\u201320.","journal-title":"Hypertension"},{"key":"1786_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/01.HYP.29.1.394","volume":"29","author":"P Li","year":"1997","unstructured":"Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1\u20137) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394\u2013400.","journal-title":"Hypertension"},{"key":"1786_CR13","first-page":"175","volume":"81","author":"SZ Fan","year":"1995","unstructured":"Fan SZ, Yu HY, Chen YL, Liu CC. Propofol concentration monitoring in plasma or whole blood by gas chromatography and high-performance liquid chromatography. Anesth Analg. 1995;81:175\u20138.","journal-title":"Anesth Analg"},{"key":"1786_CR14","doi-asserted-by":"publisher","first-page":"e0199373","DOI":"10.1371\/journal.pone.0199373","volume":"13","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang J, Liang J, Feng D, Deng F, Yang Y, Lu Y, Hu Z. Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1\u20137)-Mas axis and eNOS phosphorylation. PLoS ONE. 2018;13:e0199373.","journal-title":"PLoS ONE"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-022-01786-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:02:56Z","timestamp":1659070976000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-022-01786-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1186\/s12871-022-01786-3","relation":{},"ISSN":["1471-2253"],"issn-type":[{"type":"electronic","value":"1471-2253"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were carried out in accordance with the approved Institutional Review Board (IRB) protocols at the Medical College of Wisconsin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}